CAR-T for R/R B-NHL

Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma

This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.

Inclusion Criteria:

• Histological detection confirmed CD19/CD20/CD22/CD30 postive non-Hodgkin lymphoma
• Recieved more than 2 lines of chemotherapy
• With contraindications of hematopoietic stem cell transplantation or relapse after hematopoietic stem cell transplantation
• Expected survival more than 3 months
• Karmofsky performance score ≤ 60, and ECOG ≥ 2.
• Enough organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT < 2 × upper limitation of normal; SpO2 > 92%
• CBC results: Hb ≥ 80g/L, ANC > 1 × 10E9/L, Plt ≥ 50 × 10E9/L
• Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion
• With measurable disease
• Written informed consent could be acquired

Exclusion Criteria:

• Received immunol suppression treatment or steroids in recent 1 week before recruitment
• Uncontrolled infection
• HIV positive patients
• Active HBV or HCV infection
• Women in pregnancy and lactation
• Refuse to conception control during treatment and 1 year after CAR-T infusion
• Uncured malignancies other than non-Hodgkin lymphoma
• Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma
• Inheritated immune deficiancy
• Severe heart disease